MAOB and Parkinson disease: The treatment of PD has not changed substantially in the past 30 years, with the key role of dopamine replacement therapy, including L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine agonists, supported by the use of peripheral decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and monoamine oxidase-B (MAO-B) inhibitors [17].